Steve Cutler: 'People understand what a clinical trial is now'
America will continue to be the focus. While Iconâs business is currently split evenly between the US and Europe (with the rest of the world accounting for 20 per cent), around two-thirds of all mandates come from US pharma companies. That reality is reflected in the fact that Cutler, like his predecessor Ciaran Murray is largely based over there. However, the acquisition will double Iconâs resources in the important Japanese market and in China. Where Icon previously had strategic partnerships â arrangements that deliver substantial work and revenues â with 40 per cent of...